BDNF Research & Listing Availability

How it works

BDNF is synthesised inside neurons as a 247-residue precursor called proBDNF, which is cleaved by furin and plasmin (and by extracellular matrix metalloproteinases after secretion) to produce the mature 119-amino-acid neurotrophin that does the work attributed to "BDNF" in most of the literature.[1][3] Mature BDNF binds the tropomyosin receptor kinase B (TrkB) on the post-synaptic membrane, drives receptor dimerisation and autophosphorylation, and switches on three parallel downstream cascades — Ras-MAPK (which drives transcription of plasticity genes), PI3K-Akt (which suppresses apoptosis and supports dendritic-spine growth), and PLCγ-IP3 (which raises intracellular calcium and enables long-term potentiation at glutamatergic synapses).[2] The uncleaved proBDNF precursor binds a different receptor — p75NTR — with the opposite valence, triggering pro-apoptotic and synapse-pruning programs, so the proteolytic balance between proBDNF and mature BDNF acts as a regulated checkpoint on plasticity versus pruning rather than a simple "more is better" dial.[3] BDNF expression is itself activity-dependent: neuronal firing, exercise, and antidepressant exposure all up-regulate BDNF transcription, which is the mechanistic basis for nearly every clinical-translation program in the field.[2][4]

Active research areas

• Recombinant methionyl-BDNF in ALS (failed Phase 3, historical anchor)
  The first major clinical translation attempt — Regeneron / Amgen recombinant methionyl human BDNF in amyotrophic lateral sclerosis — failed to meet its primary endpoint in a 1,135-patient Phase 3 trial reported in 1999, with poor blood-brain-barrier penetration and a serum half-life of only a few minutes implicated as the dominant translational obstacles.[5][10] This trial is the reason the field largely abandoned systemic recombinant-protein delivery and pivoted to gene therapy and small molecules.
• AAV2-BDNF gene therapy in early Alzheimer's disease
  A Phase 1 trial (NCT05040217) is delivering BDNF directly into the entorhinal cortex via stereotactic AAV2 injection in patients with mild cognitive impairment and early Alzheimer's disease, with the explicit goal of bypassing the blood-brain-barrier problem that sank the ALS program.[6][10] Primary endpoints are safety and tolerability; secondary endpoints include cognitive and biomarker measures.
• Small-molecule TrkB agonists (7,8-DHF, R13)
  7,8-dihydroxyflavone, a small orally-bioavailable flavonoid identified by Ye and colleagues, was reported to selectively activate TrkB and reproduce BDNF-like behavioural and electrophysiological effects in rodent models of depression, Alzheimer's disease, and stroke.[8] A more drug-like prodrug, R13, was developed to improve oral bioavailability and CNS exposure.[11] The proximal binding target and selectivity of these molecules remain actively debated in the chemical-biology literature.
• BDNF dependence of ketamine's antidepressant action
  Autry et al. showed in 2011 that ketamine's rapid antidepressant-like behavioural effects in mice depend on de novo BDNF protein synthesis and on intact TrkB signalling — conditional BDNF knockout mice lose the antidepressant response — making BDNF release the leading mechanistic hypothesis for rapid-acting antidepressants and the basis for an entire downstream literature on TrkB-positive allosteric modulators in treatment-resistant depression.[9]
• Val66Met polymorphism and activity-dependent BDNF release
  A common single-nucleotide polymorphism in the human BDNF gene (Val66Met, rs6265, ~25–30% allele frequency in populations of European ancestry) reduces activity-dependent secretion of BDNF from the regulated secretory pathway and is associated with smaller hippocampal volume and modestly worse episodic memory in carriers.[7] Whether the polymorphism predicts response to antidepressants or to exercise-based interventions remains under active investigation across multiple cohorts.